Minimal Residual Disease Testing Market Analysis

Minimal Residual Disease Testing Market Analysis

To get key market trends

  Download Free Sample

Based on technology, the minimal residual disease testing market is segmented as flow-cytometry, polymerase chain reaction (PCR), next generation sequencing (NGS), and others. The polymerase chain reaction (PCR) held the considerable market share in 2022 and was valued at over USD 606 million. The significant segment progression is primarily attributed to novel technological advancement and an increase in the awareness of benefits related to the use of digital PCR (dPCR). This highly sensitive digital polymerase chain reaction allows absolute quantification through accurate molecular detection.
 

In the coming years, the popularity of minimal residual disease PCR test will produce even greater amounts of data in real-time through the integration of big data and artificial intelligence that will effectively reduce the mortality associated with cancer. Thus, the novel advancements, the emergence of integrative technologies that promote precision & reduce turn-around time, and associated benefits are projected to accelerate the market evolution.
 

Based on application, the minimal residual disease testing market is segmented as lymphoma, leukemia, solid tumors, and others. The lymphoma segment held a dominant market share in 2022 and was valued at around USD  891 million. The increasing prevalence of lymphoma is anticipated to drive the market in the forecast years. As per the American Cancer Society, in 2021, around 90,300 people were diagnosed with lymphoma in the U.S. This disease burden is expected to reach higher with each passing year. The common symptoms of having lymphoma include swelling of lymph nodes in neck, in armpits or groin.
 

Moreover, immune system disorders comprising HIV/AIDS, autoimmune disorders comprising rheumatoid arthritis, and other factors are significantly contributing to the surging incidence of blood cancer disorders. The next-generation minimal residual disease testing model will be highly sensitive & specific, incorporating novel technologies to show how well the patient has responded to treatment.
 

Based on end-use, the minimal residual disease testing market is segmented as hospitals, specialty clinics, diagnostic centers, and others. The hospitals segment is projected to reach more than USD 1.9 billion by 2032. This high market share is owing to the rising prevalence of cancer requiring minimal residual disease testing, soaring use of novel cancer tests in hospital settings, and the subsequent number of hospital admissions among others. The availability of a broad spectrum of kits for performing these tests with proven accuracy is set to drive product preference in hospitals. Growing admissions with cancer ailments and growing disease screening initiatives along with the accessibility to board-certified healthcare professionals are some other variables that are augmenting the segment enlargement positively.
 

Also, the rising disease burden in developed economies with enhanced healthcare infrastructure is projected to stimulate the diagnosis & treatment rate at hospitals. As a result, accessibility to an effective diagnosis coupled with the rising prevalence of cancer diseases and associated conditions will boost the patient visits to hospitals.
 

North America minimal residual disease testing market is anticipated to expand at a considerable pace to reach around USD 1.8 billion by 2032. The growing prevalence of cancer and the growing adoption of advanced cancer diagnostic test are some of the major factors that are driving the market growth in the country. For instance, as per the American Cancer Society, in 2022, around 1,918,030 new cancer cases and 609,360 cancer deaths were reported in the U.S.
 

Moreover, the rising patient influx associated with several chronic blood cancer disorders including leukemia, lymphoma, and myeloma among others is leading to increased product demand across several states in the U.S. According to the American Cancer Society, in 2021, 61,000 leukemia cases were reported in the U.S. As a result, minimal residual disease testing is widely adopted for residual disease & recurrence monitoring in patients with early-stage cancer by hospitals & specialty clinics in the country.